The Cannabis World Congress & Business Exposition (CWCBExpo) will be held between June 2-4, 2022, at the Javits Convention Center, Hall 3A, in New York City. Industry heavyweights, the foremost innovators, and pioneering thought leaders will take the stage to discuss emerging trends in cannabis, hemp, and allied sectors. The expo will provide a high-quality business-focused attendee base located in the premier East Coast US cannabis and hemp market. The three-day event will feature an Inside the Industry: Thought Leadership Series in an interactive “Talk Show” format. Co-hosts will include Carl Cameron, veteran journalist and former FOX News reporter; Faye Coleman, Founder and CEO of Pure Genesis, cannabis pioneer and entrepreneur Calvin Frye, and Gretchen Gailey, Chief Strategist at CWCBExpo. The Thought Leadership series will address distinct aspects of the sector each day. Day 1, Thursday, will focus on Investing and Industry Progress, Day 2 will address Policy and Legislation, and Day 3 will explore new developments in Cannabis and Lifestyle. The sessions will be educational and relevant to both the local landscape and the national outlook. The conference program will also feature two keynote conversations with Chris Beals, CEO of Weedmaps, along with Mona Zhang, States Cannabis Policy Reporter, POLITICO, on Thursday, Jun 2; and with Nick Kovacevich, CEO of Greenlane Holdings, along with Tim Seymour, Co-host, CNBC Fast Money. In addition to the wide array of expert speakers and eminent business people in attendance, the summit will host hundreds of exhibitors showcasing cutting-edge product innovations and the latest services. The event shall also host a Networking Mixer on Thursday, June 2, from 5 – 7 pm, sponsored by Weedmaps, so that attendees can network or relax ahead of the second day of the conference. On Friday, June 3, from 6 – 10 pm, CWCBExpo will host the Industry Yacht Party, where attendees can eat, drink and dance with their peers while savoring the majestic New York City skyline. This is a premier networking and deal-making opportunity. To attend either or both events, registered attendees must purchase a Networking Mixer Ticket or an Industry Yacht Party Ticket. Get your tickets now at the best price! Why wait? Cannabis Week, anchored by CWCBExpo, will take place from Monday, May 30 to Sunday, June 5, 2022, and will foster collaboration between the entire cannabis industry through industry deep dives, networking events, and lead-generation opportunities.  Several events will take place during the week throughout New York City. To learn more about Cannabis Week, event itineraries, available offers, and discounts, visit  https://cwcbexpo.com/cannabis-week For more information about the CWCBExpo, please visit https://cwcbexpo.com/

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long, strange trip. Used for millennia in spiritual quests, associated with hippies and currently outlawed by the US Government (though legal in Oregon and decriminalized in various cities and states), Silo Pharma still believes in these medicinal mushrooms. But why? The National Center for Biotechnology Information (at The National Library of Medicine), offers answers:

• In addition to the known recreational, spiritual, and religious uses of magic mushrooms, there is significant medicinal value, as evidenced by anecdotal reports and scientific studies.
• With the increase in the rate of mental disorders globally, now exacerbated by COVID-19, psychedelic-assisted psychotherapies, particularly psilocybin-assisted psychotherapies, may alleviate some of the challenges that face conventional psychiatric medicine.
• To date, over 27,000 scientific articles have been published on psychedelic drugs, with over 1000 particularly on psilocybin. Currently, psilocybin is the most studied psychedelic.
• Of all psychedelic drugs, psilocybin is reported to have the most favorable safety profile…the vast evidence-based data that exist for psilocybin alone suggest that psilocybin may be the most efficacious psychedelic drug for treating [numerous] disorders…
• In addition to having the potential to treat mood and anxiety disorders, psilocybin has also demonstrated analgesic effects as evidenced by numerous clinical studies on the treatment of cluster (“suicide”) headaches, intractable phantom-limb pain (“PLP”), and chronic pain. … In some cases, psilocybin was comparable to or more efficacious than traditional medications such as opioid analgesics…
• Globally, the psychedelic therapeutic market is predicted to reach a valuation of $6.8 billion by 2027, from USD 2 billion in 2019, at a growth rate of 16.3%. The neurogenic market including mental health drugs, therapeutic services, neurodegeneration drugs and cognitive enhancement was valued at USD 373 billion.

Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021;26(10):2948. Published 2021 May 15. doi:10.3390/molecules26102948 Psilocybin’s potential in combating neuroinflammation could change medicine as currently practiced, particularly regarding dementia and CNS disorders. According to “Psychedelics for Brain Injury: A Mini-Review,” neuroinflammatory states occur with diseases such as Alzheimer’s, and Parkinson’s. “There are currently three main classes of anti-inflammatory drugs: non-steroidal anti-inflammatory drugs (NSAIDs), steroids such as prednisone, and biologics which act like sponges to “soak up” inflammatory cytokines. Psychedelics may represent a fourth class of anti-inflammatory drug.” Eric Weisblum, Silo’s CEO, said, “Successful dosing and collection of blood samples from enrolled [TrPR] patients is an important milestone that demonstrates the progress being made … to examine the effects of psilocybin as an anti-inflammatory agent.” Silo’s commitment to psilocybin and anti-inflammatory research includes:

• Executing an option agreement with the University of Maryland, Baltimore studying novel system-homing peptides that could potentially “home to the inflamed CNS [central nervous system] and can differentiate between diseased and healthy CNS tissue.” This could be highly beneficial to multiple sclerosis (“MS”) patients as current treatments are “… given orally or parenterally and their use is associated with various side effects … a specific CNS-homing peptide would enhance the efficacy of the treatment and help limit the side effects significantly.(1) According to Silo, “These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.”
• Collaborating with the University of California San Francisco (“UCSF”) to study the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder, and chronic back pain. Weisblum says, “Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder.  Psilocybin and related compounds have shown strong anti-inflammatory effects in non-human animals, raising the possibility that reducing inflammation is a possible mechanism underlying psilocybin’s positive treatment effects in multiple disorders…”
• Teaming with the University of Maryland, Baltimore, for patented Homing Peptides to target Rheumatoid Arthritis. According to a Silo news release, “The ability … to target inflamed endothelium suggests [homing peptides] could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

(1) Acharya, Bodhraj et al. “A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.” Molecular and cellular probes vol. 51 (2020): 101530. doi:10.1016/j.mcp.2020.101530 For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• J.D. Power survey reports range was factor most cited in deciding what EV to buy
• Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space
• Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies

One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 Energy.gov study reported that the median rage for EV last year was 234 miles (https://ibn.fm/tvIzU). Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, is focused on improving that number; the company is currently actively testing advanced battery technology which can provide a range of 600-plus miles on a full charge at the pack level (https://ibn.fm/4H957). “When modern all-electric vehicles (‘EV’) were introduced in model year (‘MY’) 2011, there were four models available with ranges spanning from 63 to 94 miles with a median range of 68 miles,” reports Energy.gov. “Over time, the number of models and the ranges of EVs have increased. By MY 2021, the maximum range for an EV had more than quadrupled to 405 miles on a single charge, while the median range was 234.” This range limitation is causing concern for consumers. Forbes Wheel reports that in a 2021 J.D. Power survey, range was the factor most cited in deciding what EV to buy (https://ibn.fm/qx4Yy), and a ScienceABC article noted that more than 80% of consumers were hesitant to buy an electric vehicle because of range anxiety, along with the higher purchase cost (https://ibn.fm/cl3Om). “We have grown accustomed to conventional internal combustion engine (‘ICE’) vehicles for more than a century,” the article states. “Thus, there is a robust network of gas stations in most countries. In the US, an average American is just four minutes away from a gas station. Meanwhile, an average American lives 30 minutes away, on average, from a Tesla charging station. Tesla accounts for nearly 80% of electric car sales in the US, so looking at the statistics, the development of range anxiety is unsurprising.” Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space, thereby alleviating range anxiety for potential EV buyers. Earlier this year, the company announced an update on its next-generation solid-state polymer battery technology, which is a significant advancement over today’s current lithium-ion batteries. “Mullen’s testing of solid-state polymer cells reveals the potential for a 150-kilowatt-hour battery pack that delivers over 600-plus miles of range and highlights an 18-minute DC fast charge which can yield over 300 miles of range,” the announcement says. “Mullen is working towards utilizing solid-state polymer battery packs in its second-generation Mullen FIVE EV Crossovers, with in-vehicle prototype testing set for 2025.” Recognizing the importance of battery and range in the success of an EV, Mullen is also exploring other advanced battery technologies, including lithium-sulfur and lithium-iron-phosphate. The company is committed to do whatever is necessary to deliver EV batteries that will surpass today’s existing lithium-ion technology and offer a host of benefits, such as increased efficiency, energy density, and range, while also lowering the cost, weight, thermal and environmental risks. “We’ve conducted successful testing and will begin pack level development next,” states Mullen CEO and chair David Michery. “The test data collected shows an impressive outcome and future for solid-state batteries. To sum up, we tested our 300 Ah (ampere-hour) cell, which yielded 343 Ah at 4.3 volts, and the results surpassed all expectations. We can say with almost certainty that this technology, once implemented on the Mullen FIVE, will deliver over 600 miles of range on a full charge. The future is bright for Mullen Automotive.” Mullen is a Southern Californian automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
• CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
• Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology (https://ibn.fm/1vach). “In our national survey on mental health and coronavirus, we found that the COVID-19 pandemic has affected the mental health of 59% of people in the United States,” reported a recent SingleCare article (https://ibn.fm/IBtft). “Dismantling the stigma around mental illness is important now more than ever.” SingleCare reported that an estimated 970 million people worldwide have a mental-health or substance-abuse disorder, with anxiety being the most common mental illness in the world, impacting 284 million people. Other significant mental-health challenges that are leading causes of serious disabilities include major depression, anxiety, alcohol-use disorders, schizophrenia, bipolar disorder, and dysthymia, or persistent mild depression. Cybin has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. Most recently the company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance. “Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Doug Drysdale, Chief Executive Officer of Cybin. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” continued Drysdale. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.” The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset facilitates this; the system is equipped with hi-tech sensors that record brain activity and report a participant’s experience using structured questionnaires and validated assessments during study visits and at follow-up. Cybin and Kernel signed a partnership agreement in January 2021 that gives Cybin exclusive interest in any innovations discovered or developed through the company’s independent analysis of the study findings, while Kernel retains the same rights relating to its Kernel technology. “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Kernel founder and CEO Bryan Johnson. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help to advance these powerful new therapies for patients.” Cybin is currently working on three active drug programs: CYB003 targets major depressive disorder and alcohol use disorder, CYB004 is focused on anxiety disorders and CYB005 is studying neuroinflammation. The company has completed more than 140 preclinical studies and is making steady progress toward FDA IND filings; in addition, Cybin has developed 50 novel compounds and completed more than 10 patent filings across three patent families. The company is collaborating with a network of world-class partners and internationally recognized scientists as it progresses on its mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices
• The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug
• With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity
• CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway
• Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking incidents
• The company’s sports advisory board is headlined by NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach
• Odyssey is guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems and forging strategic partnerships

Odyssey Group International (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care. The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships. Product Portfolio Pharmaceuticals Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.

PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (“CTE”).

• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.

Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity. Medical Devices Odyssey is also developing two medical device candidates:

• CardioMap(R) is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.

When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.

• Save-A-Life (“SAL”) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.

Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks. Market Opportunities Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%. It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach. With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028. Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications. Management Team Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University. Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University. Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Hosted by CoinDesk, the 2022 Consensus festival is slated for June 9-12, 2022, in Austin, Texas
• The festival features 15,000+ attendees, 400+ speakers, and 250+ event sponsors, catering to all sides of blockchain, crypto, Web3, NFTs and the Metaverse
• Web3 is the future of the internet – creating a decentralized technology that removes the control from the big tech companies and places it back in the hands of the users
• Venture Capitalist firm Andreessen Horowitz announced a $4.5 billion fund aimed at Web3; with one third of the funds dedicated exclusively to seed deals
• Coinbase has become the first crypto-based company to be listed on the Fortune 500, making history as the first of its kind to make the list

As worldwide interest in cryptocurrency grows, so do the conventions dedicated to the sector. One of the largest and longest-running crypto-focused events, the 2022 Consensus festival hosted by CoinDesk, will take place June 9-12, 2022, in Austin, Texas, and is expected to feature all sides of blockchain, crypto, Web3, NFTs and the Metaverse. Consensus aims to create a one-of-a-kind experience on how crypto is remaking the worlds of finance, investing, culture, entertainment, marketing, governance and more. For four days, thousands of attendees will get the opportunity to listen to more than 400 speakers from the industry. There will also be networking events scheduled throughout the festival, allowing more intricate connections to be made amongst guests, speakers and over 250 sponsors. Tickets for the event are still available at https://www.coindesk.com/consensus2022/. The cryptocurrency industry changes constantly, and so do the power players in the market. For example, Coinbase (NASDAQ: COIN), a leading cryptocurrency exchange platform in the United States, has made history as the first cryptocurrency company to break into the Fortune 500. Despite the recent struggles to meet analyst expectations, the company achieved significant results in 2021, catapulting it onto the prestigious list at number 437 (https://ibn.fm/siXNC). Although 2021 seemed to be a good year for the crypto industry, the start of 2022 has proven difficult for most of the market. With Bitcoin’s market cap lingering around $1.31 trillion and a devastating crash of the Terra stablecoin – the industry seems to be stuck in a holding pattern, waiting for the next shoe to drop. Even with such a gloomy overcast on the crypto world, not all venture capitalists are using the same wait-and-see philosophy. Silicon Valley venture capital firm Andreessen Horowitz has closed on its newest crypto fund ($4.5 billion), doubling its previous funding round. The fund highlights the widening interest of the firm’s limited partners in increasing their exposure to crypto startups. The firm has specified that one-third of this massive fund will be specifically earmarked for seed deals exclusively. One area of general interest is the Web3 future – which many are willing to spend the funding for despite recent turbulence in the industry (https://ibn.fm/N5SSf). The Web3 protocol has been in the making and on the radar of venture capitalists for quite a while. Back in the fall of 2021, Chris Dixon, a partner of Andreessen Horowitz, wrote: “We are now at the beginning of the Web3 era, which combines the decentralized, community-governed ethos of Web1 with the advanced, modern functionality of Web2.” The Web3 concept will take the power of the internet out of the hands of the big tech companies and place it back into the hands of the users utilizing blockchain technology (https://ibn.fm/wzsJc). Like cryptocurrency decentralizes finance, the Web3 protocol would decentralize technology – taking the ownership of the internet out of the hands of big companies like Google/Alphabet Inc. (NASDAQ: GOOG), Amazon.com, Inc. (NASDAQ: AMZN), and Facebook/Meta Platforms, Inc. (NASDAQ: FB), leading to the creation of what proponents describe as an egalitarian internet.

• A key to becoming “irreplaceable” is to communicate clearly, Inc. article suggests
• Nowigence believes the capability to communicate clearly can be found in its high-proprietary, cloud-based knowledge management tool: Pluaris
• Pluaris reads and analyzes information across the internet 24/7, then organizes and optimizes gathered data for storage, analysis, synthesis and retrieval

As companies — and individuals — work to make themselves irreplaceable, an Inc. newsletter notes that communicating clearly is a key skill (https://ibn.fm/0863V). Nowigence’s Inc. (NOWG) Pluaris, a high-proprietary, cloud-based knowledge management tool, makes clear communication easier than ever before. One solution, the article points out, is to distinguish yourself — or your company — from the competition by communicating clearly. “Every job requires clear communication,” the article states. “A carpenter needs to explain clearly to the rest of the team what he’s doing and when he’s doing it. The sales [team] needs to broadcast the company’s unique [selling] points and draw leads to the close. The owner of the business needs to set targets and expectations so that team members know exactly what they have to do and customers know exactly what they’re getting.” The capability to communicate clearly is rooted first in the ability to gather and organize information in an accessible, concise manner and then share that information with key individuals or organizations in a single, accessible platform. When an individual can do that, critical information is received, understood and acted upon, and the conveyors of that information become essential team members. Professional knowledge workers who are responsible for researching, studying and sharing information with others and lifelong learners alike will be thrilled with Nowigence’s Pluaris and its ability to read and analyze information across the internet 24/7. Once this information is gathered, Pluaris then uses exclusive machine learning and natural language processing techniques to analyze the content; transform, link and taxonomize data; and then optimize for storage, analysis, synthesis and retrieval. This complete and thorough process results in information that provides answers, connections, notes and insight. And just as importantly, Pluaris provides a single platform so that all this critical information can be clearly and concisely communicated with others, allowing teams to work collaboratively from anywhere in the world as they discuss problems, identify solutions and make decisions. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Acquisition of 85,000-square-foot West Virginia manufacturing campus is key milestone in company’s vision to become household name
• Facility checks all boxes company wanted in first design and manufacturing location
• Kronos is focused on designing and manufacturing next-generation wellness consumer electronics products and PPE solutions

A plan started more than two years ago by Kronos Advanced Technologies (OTC: KNOS) is a step closer to fruition today; the company recently announced closed on the acquisition of an 85,000-square-foot West Virginia manufacturing campus that will be retrofitted to produce advanced, proprietary air-purification devices and other wellness products (https://ibn.fm/FQS30). “Nearly two years ago, we set into motion a strategic plan to transform Kronos from a marketing and fulfillment company, positioned within the fragmented market space of air purification, into a globally dominant consumer product design and manufacturing company,” said Kronos COO and CTO Joseph Florence. “Our vision is for Kronos to become a household recognized, customer-centric design and manufacturing company providing products that improve the human condition by enhancing the air we breathe, the water we drink, the food we eat, and the environment we live in. This acquisition is a key foundational milestone in our transformation.” The just-finalized acquisition, which required significant levels of capital and management investment, is essential to Kronos’ detailed, specific transformation plan because the plant checked all the boxes the company desired for its first design and manufacturing campus. The 10-acre location, which for more than two decades produced advanced electronics such as high-density circuit boards for aviation, military, industrial and medical products, includes warehouses and a 62,000-square-foot manufacturing facility with all infrastructure and equipment needed to immediately begin contract assembly. In addition, noted Florence, “the acquired manufacturing campus is located within a day’s drive of one-half of the USA population and one-third of the Canadian market. This demographic represents a significant portion of our future customers. Kronos is confident that this acquisition will enable us to focus on the efficient fulfillment of our current product line, the utilization of our recently acquired equipment to begin offering contract manufacturing services, and the ability to initiate the transition of our conceptual designs into production.” KNOS officials have worked closely with the state of West Virginia and the community of Parkersburg, where the campus is located. Company representatives noted that the job possibilities for the area are enormous, with some 300 new jobs anticipated to open by next month. The company also acknowledged the support of the West Virginia Economic Development Agency (WVEDA) and the city as KNOS has worked to take this next step forward. “This community has a long history of providing a competitive location for manufacturers, and we are proud to now be in the great state of West Virginia,” said Florence. “We are developing the manufacturing workplace of the future—from our development of industry 4.0 next-generation robotic manufacturing processes to our lean and collaborative work environment. We are poised to succeed.” Moving forward, the company is committed to manufacturing completely on American soil. Kronos is focused on next-generation wellness consumer electronics products and PPE solutions. Originally founded in 2002 and funded by the U.S. military to develop electrostatic air movers, KNOS next evolved into the consumer air-purification space, initially focusing on developing, marketing and selling its proprietary air movement and purification technology. Its proprietary technology is now also being implemented in multiple standalone products for businesses, homes and vehicles of all types to move, sterilize and filter air. Kronos Advanced Technologies is exploring broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices, including schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and automobiles and commercial aircraft cabins. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Legislative changes driven by public policy commitment to slashing greenhouse emissions are driving increased demand for renewable natural gas (“RNG”)
• RNG generation avoids toxic emissions of methane, a greenhouse gas with a warming potential 25–34 times greater than Carbon Dioxide
• EverGen, Canada’s established renewable natural gas producer, appears ready to act on this rising market opportunity in Canada and beyond; responds with plans to consolidate projects, enter merger, and acquisition transactions, and grow core portfolio projects

“We set up EverGen to execute on space that has a tremendous amount of tailwind”, are the words Chase Edgelow, co-founder and CEO of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), an independent renewable energy producer, used in a recent interview with Proactive — one of the world’s fastest-growing financial media portals — to describe how the company is positioned within the current renewable energy marketplace. “From the organics management side, municipalities are increasingly looking to decarbonize. One of the biggest ways they can do that is by ensuring that minimal organics are going to landfills and no methane is going into the atmosphere. Those are the types of services that we provide on the front end and then green energy on the back end”, he continued, presenting details of the company’s 2021 financial results and plans for the future. As concerns about the climate threat grow, countries around the world take urgent climate action to combat climate change and decarbonize the economy. Leading up to COP26 — the most recent annual UN climate change conference – 64 countries worldwide have pledged or legislated their commitment to achieving net-zero greenhouse emissions in the coming years. As the global push to reduce greenhouse gas emissions has gained momentum, so did RNG — a waste-derived fuel used to power homes, businesses, and vehicles and one of the promising decarbonization technologies which prevents methane from polluting the air. Instead of allowing this greenhouse gas with a warming potential 25–34 times greater than Carbon Dioxide to enter the atmosphere, RNG technology turns it into a usable energy source (https://ibn.fm/DRgHI). EverGen produces RNG by solving two problems at once. Not only does it offer an organic waste management solution, but it also transforms this waste — which is one of the biggest methane culprits – into a non-fossil fuel form of natural gas. The World Biogas Association estimates that organic waste from food waste, food production, farming, landfill, and wastewater treatment creates around 25% of human-caused global emissions of methane (https://ibn.fm/UCByL). The Canadian government has demonstrated a strong commitment to achieving net-zero greenhouse gas emissions by 2050 by enacting The Canadian Net-Zero Emissions Accountability Act, heightening the industry’s interest in RNG. Following the public policy’s lead, commercial entities also take resolute action. For example, the country’s natural gas utilities have set an ambitious target of 5% RNG blended into natural gas streams by 2025 and 10% by 2030. To seize this rising market opportunity and continue to participate in the growth and consolidation of the RNG industry, EverGen entered a letter of intent with Grow the Energy Circle Ltd. to acquire a 67% interest in a biogas facility in Alberta. The company will work with GrowTEC to develop and expand the RNG output at the facility, which is considered a cornerstone asset in a strategic jurisdiction for the Canadian RNG producer. According to the company, this move is one of many to follow. “For us, it’s about consolidating projects, announcing merger and acquisition transactions, and growing our core portfolio projects to six and beyond. We have portfolio projects across Canada, allowing us to leverage our operational expertise from one side of the country to the other and bring projects that had been sitting on the fifty-yard line to the hundred-yard line — getting them into production and into producing green energy for the utilities, and giving Canadians real options for energy diversification”, concluded Edgelow in the interview, unveiling strategy for the company’s expansion in times to come. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology
• The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastes
• Lexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applications
• The company operates several subsidiary companies to focus on different commercial opportunities

Ever since acquiring its first intellectual property (“IP”) that subsequently formed the basis of its first two patent application filings in 2014, biotechnology company Lexaria Bioscience (NASDAQ: LEXX) has grown the number of patents granted and patent applications exponentially, with 25 patents granted worldwide as of April 2022. The latest patent, the 10th granted in the United States, represents the first-ever patent for the use of DehydraTECH(TM) drug delivery technology in the enhanced delivery of antiviral drugs. Described by CEO Chris Bunka as “another validation of the versatility of our DehydraTECH drug technology,” the award of the IP protection marks a key step toward the ultimate monetization of DehydraTECH, according to an April 21 news release (https://ibn.fm/bzEzf). This monetization, Lexaria’s annual report (Form 10-K filing) for the fiscal year ended August 2021 notes (https://ibn.fm/e1wLG), will be realized through the company’s focus on R&D and subsequent strategic partnerships with licensees. “Lexaria’s formulation and process-oriented operations are primarily conducted in its own laboratory and validated through third-party testing in preparation for partnering with industry leaders for adoption into their consumer products and/or drugs. Other than for R&D purposes, Lexaria does not produce, manufacture, market, or distribute drugs,” the filing reads. “Our business plan is currently focused on the development of strategic partnerships with licensees for our patented DehydraTECH technology in exchange for upfront and/or staged licensing fees and/or royalty payments over time.” This focus has been influenced by numerous learnings through the years, some of which have involved experimentation with consumer product development that included brewed tea, coffee, protein bars, candies, drink mixes and several other product types. Discoveries made through innovative formulation work drives Lexaria’s technology and licensing strategies. According to the company’s most recent quarterly report for the three months ended February 28, 2022 (https://ibn.fm/Wd7Cw), Lexaria operates wholly owned subsidiaries focused on commercial opportunities which include –Lexaria Hemp Corp. focused on primarily US-based business-to-business (“B2B”) CBD opportunities;  Lexaria Pharmaceutical Corp., focused on registered drug development and advancement;  – and Lexaria Nicotine LLC., owned 16.67% by giant tobacco company Altria, which is focused on oral nicotine development as an alternative to combusted or vaped nicotine (https://ibn.fm/vOB7q). Lexaria Pharmaceutical Corp. is investigating the potential for new registered drug products for hypertension, anti-viral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes. This is where the largest long-term value creators for the Company are developed. Lexaria CanPharm Corp. operates a state-of-the-art Health Canada-licensed laboratory capable of developing novel cannabinoid and many other types of formulations for potential commercialization. Much of Lexaria’s most secret development work is carried out in that laboratory by trusted scientists employed by the Company. These subsidiaries sublicense DehydraTECH in their respective business sectors for the delivery of fat-soluble molecules and drugs to other companies which is Lexaria’s central plan to generate highly profitable revenue streams over long periods. Additionally, Lexaria will continue pursuing its pending patent applications to further bolster shareholder value. In addition, the company “will continue to seek beneficial acquisitions of intellectual property” if and when it believes it is advisable to do so. Lexaria is a drug delivery company focused on developing and licensing its proprietary DehydraTECH technology for improved delivery and rapidity of bioactive compounds in orally delivered and topical products, as well as enhanced customer experiences by masking unwanted tastes. The DehydraTECH technology has been proven to enhance the bioavailability of a broad range of fat-soluble active pharmaceutical ingredients (“APIs”), thereby improving the way they enter the bloodstream, lowering dosing, and facilitating healthier oral ingestion methods. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX